Axogen, Inc. (AXGN): Price and Financial Metrics


Axogen, Inc. (AXGN): $11.09

0.06 (+0.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AXGN POWR Grades

  • Growth is the dimension where AXGN ranks best; there it ranks ahead of 93.01% of US stocks.
  • AXGN's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • AXGN ranks lowest in Momentum; there it ranks in the 10th percentile.

AXGN Stock Summary

  • AXOGEN INC's stock had its IPO on March 27, 1990, making it an older stock than 85.77% of US equities in our set.
  • The ratio of debt to operating expenses for AXOGEN INC is higher than it is for about 33.13% of US stocks.
  • As for revenue growth, note that AXGN's revenue has grown 4.4% over the past 12 months; that beats the revenue growth of 32.58% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AXOGEN INC are HEAR, MAPS, ATRC, CSII, and SGHT.
  • Visit AXGN's SEC page to see the company's official filings. To visit the company's web site, go to www.axogeninc.com.

AXGN Valuation Summary

  • AXGN's EV/EBIT ratio is -18.6; this is 316.28% lower than that of the median Healthcare stock.
  • AXGN's price/earnings ratio has moved down 15.5 over the prior 243 months.

Below are key valuation metrics over time for AXGN.

Stock Date P/S P/B P/E EV/EBIT
AXGN 2022-11-25 3.5 4.7 -16.4 -18.6
AXGN 2022-11-23 3.5 4.6 -16.0 -18.2
AXGN 2022-11-22 3.5 4.6 -16.1 -18.3
AXGN 2022-11-21 3.4 4.5 -15.9 -18.1
AXGN 2022-11-18 3.7 4.9 -17.2 -19.4
AXGN 2022-11-17 3.6 4.8 -16.9 -19.1

AXGN Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 39.58%.
  • Its year over year revenue growth rate is now at 6.93%.
  • Its 2 year price growth rate is now at -1.21%.
AXGN's revenue has moved up $27,245,000 over the prior 33 months.

The table below shows AXGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 133.957 -18.942 -28.819
2022-06-30 128.202 -18.629 -31.642
2022-03-31 127.328 -13.636 -31.8
2021-12-31 127.358 -13.405 -26.985
2021-09-30 128.316 -9.054 -27.709
2021-06-30 130.54 -6.06 -22.047

AXGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AXGN has a Quality Grade of C, ranking ahead of 50.98% of graded US stocks.
  • AXGN's asset turnover comes in at 0.65 -- ranking 58th of 186 Medical Equipment stocks.
  • ADMT, NDRA, and APYX are the stocks whose asset turnover ratios are most correlated with AXGN.

The table below shows AXGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.650 0.821 -0.111
2021-03-31 0.625 0.816 -0.133
2020-12-31 0.633 0.808 -0.172
2020-09-30 0.651 0.806 -0.219
2020-06-30 0.661 0.808 -0.294
2020-03-31 0.706 0.829 -0.278

AXGN Price Target

For more insight on analysts targets of AXGN, see our AXGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.00 Average Broker Recommendation 1.43 (Moderate Buy)

AXGN Stock Price Chart Interactive Chart >

Price chart for AXGN

AXGN Price/Volume Stats

Current price $11.09 52-week high $13.66
Prev. close $11.03 52-week low $6.87
Day low $10.89 Volume 106,500
Day high $11.13 Avg. volume 283,991
50-day MA $11.43 Dividend yield N/A
200-day MA $9.62 Market Cap 468.96M

Axogen, Inc. (AXGN) Company Bio


AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company is based in Alachua, Florida.


AXGN Latest News Stream


Event/Time News Detail
Loading, please wait...

AXGN Latest Social Stream


Loading social stream, please wait...

View Full AXGN Social Stream

Latest AXGN News From Around the Web

Below are the latest news stories about AXOGEN INC that investors may wish to consider to help them evaluate AXGN as an investment opportunity.

Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Yahoo | November 11, 2022

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Axogen, Inc Reports 2022 Third Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2022. Third Quarter Financial Results 2022 and Business Highlights Net revenue was $37.0 million during the third quarter, an increase of 18% over the third quarter of 2021.*Gross margin was 83.3% for t

Yahoo | November 8, 2022

Axogen to Participate at Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and CFO will participate in upcoming investor conferences in November and December. Zaderej will participate in a fireside chat at the Jefferies London Healthcare Conference, on Tuesday, Nove

Yahoo | November 3, 2022

Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.

Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine.ALACHUA, Fla. and TAMPA, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that effective December 13, 2022 (the “Effective Date”), Adrian Tyndall, M.D., MPH, FACEP has been appointed as an independent member to the company’s board of directors a

Yahoo | October 31, 2022

Read More 'AXGN' Stories Here

AXGN Price Returns

1-mo 3.74%
3-mo 20.94%
6-mo 18.74%
1-year 16.00%
3-year -31.69%
5-year -58.46%
YTD 18.36%
2021 -47.65%
2020 0.06%
2019 -12.43%
2018 -27.81%
2017 214.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8496 seconds.